Landscape Capital Management L.L.C. purchased a new stake in shares of Biohaven Ltd. (NYSE:BHVN - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 18,710 shares of the company's stock, valued at approximately $699,000.
Other institutional investors also recently bought and sold shares of the company. Spire Wealth Management bought a new position in Biohaven during the fourth quarter valued at $56,000. Amalgamated Bank grew its holdings in Biohaven by 21.9% during the 4th quarter. Amalgamated Bank now owns 2,929 shares of the company's stock valued at $109,000 after purchasing an additional 527 shares during the last quarter. US Bancorp DE grew its holdings in Biohaven by 36.7% during the 4th quarter. US Bancorp DE now owns 2,971 shares of the company's stock valued at $111,000 after purchasing an additional 798 shares during the last quarter. KBC Group NV raised its position in Biohaven by 50.1% in the 4th quarter. KBC Group NV now owns 3,377 shares of the company's stock worth $126,000 after purchasing an additional 1,127 shares during the period. Finally, Diversified Trust Co lifted its stake in Biohaven by 16.6% in the fourth quarter. Diversified Trust Co now owns 5,585 shares of the company's stock worth $209,000 after purchasing an additional 795 shares during the last quarter. 88.78% of the stock is currently owned by institutional investors.
Wall Street Analyst Weigh In
A number of research firms have recently commented on BHVN. Royal Bank of Canada reaffirmed an "outperform" rating and set a $61.00 target price on shares of Biohaven in a research note on Tuesday, March 4th. Deutsche Bank Aktiengesellschaft set a $60.00 price objective on Biohaven and gave the company a "buy" rating in a research report on Thursday, March 20th. Cantor Fitzgerald reissued an "overweight" rating on shares of Biohaven in a research note on Tuesday, December 17th. HC Wainwright restated a "buy" rating and issued a $54.00 price target on shares of Biohaven in a report on Tuesday, March 4th. Finally, Morgan Stanley decreased their price objective on shares of Biohaven from $69.00 to $63.00 and set an "overweight" rating for the company in a report on Friday, March 7th. Fourteen investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Buy" and a consensus target price of $62.77.
Check Out Our Latest Stock Report on Biohaven
Insiders Place Their Bets
In other news, Director John W. Childs purchased 32,700 shares of the stock in a transaction on Tuesday, March 4th. The stock was bought at an average price of $30.47 per share, with a total value of $996,369.00. Following the transaction, the director now owns 2,320,571 shares in the company, valued at $70,707,798.37. The trade was a 1.43 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 16.00% of the company's stock.
Biohaven Stock Up 2.5 %
BHVN stock traded up $0.42 during trading on Friday, hitting $17.55. 1,576,488 shares of the company's stock traded hands, compared to its average volume of 1,124,143. Biohaven Ltd. has a 1 year low of $15.79 and a 1 year high of $55.70. The business has a fifty day simple moving average of $30.45 and a two-hundred day simple moving average of $39.57. The firm has a market capitalization of $1.79 billion, a P/E ratio of -1.88 and a beta of 1.33.
Biohaven (NYSE:BHVN - Get Free Report) last posted its earnings results on Monday, March 3rd. The company reported ($1.85) EPS for the quarter, missing analysts' consensus estimates of ($1.56) by ($0.29). On average, equities research analysts predict that Biohaven Ltd. will post -8.9 EPS for the current fiscal year.
About Biohaven
(
Free Report)
Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.
Read More
Before you consider Biohaven, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Biohaven wasn't on the list.
While Biohaven currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
